The Interaction Between Oxytocin and Serotonin
The Interaction Between Oxytocin and Serotonin on the Social-emotional Brain Networks
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 611731
- Recruiting
- School of Life Science and Technology
-
Contact:
- Weihua Zhao
- Email: zarazhao.uestc@outlook.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- health subjects without past or current psychiatric or neurological disorders
- Right-handedness
Exclusion Criteria:
- History of head injury;
- Medical or psychiatric illness.
- High blood pressure, general cardio-vascular alterations
- History of drug or alcohol abuse or addiction.
- Allergy against medications or general strong allergies
- Sleep disorders.
- Visual or motor impairments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: male oxytocin and ATD group
male subjects receiving oxytocin and ATD treatment
|
intranasal administration of oxytocin (24 IU)
oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
|
|
Experimental: male oxytocin and placebo group
male subjects receiving oxytocin and ATD-placebo treatment
|
intranasal administration of oxytocin (24 IU)
oral administration of a tryptophan-balanced mixture (78.2g)
|
|
Experimental: male placebo and ATD group
male subjects receiving oxytocin placebo and ATD treatment
|
oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
intranasal administration of placebo nasal spray
|
|
Placebo Comparator: male placebo group
male subjects receiving oxytocin placebo and ATD placebo treatment
|
oral administration of a tryptophan-balanced mixture (78.2g)
intranasal administration of placebo nasal spray
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neural processing during the emotion processing as assessed via fMRI
Time Frame: 6h after treatment
|
fMRI BOLD indices of neural processing in emotion related brain regions will be compared between the treatment groups
|
6h after treatment
|
|
Neural processing during the resting state as assessed via fMRI
Time Frame: 6h after treatment
|
Resting state activity in the emotional brain networks will be compared between the treatment groups
|
6h after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UESTC-neuSCAN-29
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.